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White spot syndrome virus (WSSV) occurs worldwide and causes high mortality and considerable economic
damage to the shrimp farming industry. No adequate treatments against this virus are available. It is generally
accepted that invertebrates such as shrimp do not have an adaptive immune response system such as that
present in vertebrates. As it has been demonstrated that shrimp surviving a WSSV infection have higher
survival rates upon subsequent rechallenge, we investigated the potential of oral vaccination of shrimp with
subunit vaccines consisting of WSSV virion envelope proteins. Penaeus monodon shrimp were fed food pellets
coated with inactivated bacteria overexpressing two WSSV envelope proteins, VP19 and VP28. Vaccination with
VP28 showed a significant lower cumulative mortality compared to vaccination with bacteria expressing the
empty vectors after challenge via immersion (relative survival, 61%), while vaccination with VP19 provided no
protection. To determine the onset and duration of protection, challenges were subsequently performed 3, 7,
and 21 days after vaccination. A significantly higher survival was observed both 3 and 7 days postvaccination
(relative survival, 64% and 77%, respectively), but the protection was reduced 21 days after the vaccination
(relative survival, 29%). This suggests that contrary to current assumptions that invertebrates do not have a
true adaptive immune system, a specific immune response and protection can be induced in P. monodon. These
experiments open up new ways to benefit the WSSV-hampered shrimp farming industry.
White spot syndrome virus (WSSV) belongs to a new virus
family, the Nimaviridae, and contains a large circular double-
stranded DNA genome of 292,967 bp (22), but isolates with
larger genomes have also been identified (AF440570) (27).
WSSV virions are ellipsoid to bacilliform, enveloped particles
with a distinctive tail-like appendage at one end and can be
found throughout the body of infected shrimp. The virions
contain one nucleocapsid with a typical striated appearance
and five major and at least 13 minor proteins (6, 20, 21, 24).
WSSV, which was first discovered in southeast Asia around
1992, is currently the most serious viral pathogen of shrimp
worldwide. It causes up to 100% mortality within 7 to 10 days
in commercial shrimp farms, resulting in large economic losses
to the shrimp farming industry (11). Shrimp culture has been a
booming business since the beginning of the 1990s, and world-
wide production was 1 million metric tons in 2002 (15). It is
one of the few sources for economic development and provides
well-paid employment in poor coastal areas (1).
Given the global environmental, the economic and sociolog-
ical importance of shrimp farming, and the constraints of high-
intensity cultivation, the development of vaccines against
WSSV would be desirable. The idea of vaccinating shrimp, or
invertebrates in general, seems to be unfeasible since they are
assumed to lack an adaptive immune response and rely solely
on innate immune responses (8). However, a recent study in
the copepod Macrocyclops albidus showed that the defense
system of this invertebrate species reacted more efficiently
after a previous encounter with an antigenically similar para-
site, implying that a specific memory may exist (9). Further-
more, immunostimulation and vaccination of shrimp with in-
activated Vibrio spp. have been reported to provide some
protection (2, 7, 19). Studies on the shrimp immune response
to viral infections are limited, although the presence of virus-
inhibiting proteins and specific upregulation of genes upon
viral infection have been demonstrated (13, 14, 16). In vivo
experiments with Penaeus japonicus demonstrated the pres-
ence of a quasi-immune response when survivors of both nat-
ural and experimental WSSV infections were rechallenged
with WSSV (25). Plasma from the surviving infected shrimp
could neutralize WSSV from 20 days up to 2 months after
infection (26). These results suggest that some sort of adaptive
immune response could exist in shrimp.
To investigate whether protection against WSSV could be
induced in shrimp by vaccination, a subunit vaccine was gen-
erated with two major structural envelope proteins of WSSV,
VP19 and VP28. Neutralization experiments with VP28 have
shown it to be involved in the systemic infection of WSSV (23).
An oral vaccination strategy was adopted because injection
vaccinations are not practically feasible in shrimp farming.
Inactivated bacteria overexpressing the WSSV envelope pro-
teins VP19 and VP28 coated on food pellets were selected for
delivery of the WSSV proteins. The onset and duration of the
observed protection were further investigated by challenging
shrimp at different time points after vaccination.
MATERIALS AND METHODS
Shrimp culture. Healthy Penaeus monodon shrimp were imported as postlar-
vae from Malaysia and maintained in a recirculation system at the facility De
Haar vissen at Wageningen University. Each shipment was tested for the pres-
ence of WSSV, monodon baculovirus, yellow head virus, Taura syndrome virus,
and infectious hypodermal and hematopoietic necrosis virus by PCR. Prior to
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each experiment, shrimp were transferred to an experimental system located at
the Laboratory of Virology at Wageningen University and stocked in 180-liter
aquariums, each fitted with an individual filter system (Eheim, Germany), heat-
ing (Schego, Germany) to 28  1°C, and continuous aeration. All experiments
were performed in artificial seawater (Instant Ocean, Aquarium Systems) at a
salinity of approximately 20 ppt.
WSSV stock. The virus isolate used in this study originated from infected
Penaeus monodon shrimp imported from Thailand in 1996. Virus stocks were
generated in the crayfish Orconectes limosus and purified from freshly extracted
hemolymph by sucrose gradient centrifugation as described by Van Hulten et al.
(23). Virus samples were stored in aliquots at 80°C.
In vivo titration and WSSV challenge. In order to mimic the natural route of
infection and to ensure a constant and reproducible challenge pressure, shrimp
were challenged via immersion. To determine the amount of virus required for
the desired challenge pressure of approximately 75% mortality, a virus stock was
prepared and titrated in vivo. Shrimp weighing approximately 1 g were immersed
in different dilutions of WSSV for a 7-h incubation period. The shrimp were
removed from the WSSV-containing water, rinsed, and moved to individual
cages to prevent horizontal transmission by cannibalism. Mortality was recorded
twice a day, and dead shrimp were tested for the presence of WSSV by PCR.
WSSV challenge after vaccination was performed identically.
PCR analysis for WSSV. Muscle tissue from the tails of shrimp was homog-
enized and mixed with 200 l of 5% Chelex 100 resin (Bio-Rad) and 16 l of
20-mg/ml proteinase K. This mixture was incubated overnight at 56°C, followed
by 10 min at 95°C to inactivate the proteinase K. The samples were tested with
two primer pairs. A 16S rRNA primer pair, 16S-FW1 (5-GTG CGA AGG TAG
CAT AAT C-3 ) and 16S-RV1 (5-CTG CTG CAA CAT AAG GAT AC-3),
amplifying a 414-bp fragment of shrimp ribosomal DNA, was used as an isolation
control. A VP26 primer pair, VP26-FW1 (5-ATG GAA TTT GGC AAC CTA
ACA AAC CTG-3) and VP26-RV1 (5-GGG CTG TGA CGG TAG AGA
TGA C-3), amplifying part of the WSSV VP26 gene, was used to screen for
WSSV-positive animals (12). Twenty-five cycles of amplification were performed
at 30 s at 94°C, 30 s at 52°C, and 50 s at 72°C for both primer pairs.
Bacterial expression of VP28 and VP19. Expression constructs were generated
for VP28 and VP19 in fusion with His6 and maltose-binding protein (MBP) tags.
The complete VP19 open reading frame was cloned as a BamHI/PstI fragment
into the pMAL-C2 vector (New England Biolabs) after PCR amplification from
the WSSV genome with primer VP19-FW1 (5-CGG GAT CCA TGG CCA
CCA CGA CTA A-3) and primer VP19-RV1 (5-GCC TGC AGC CTG ATG
TTG TGT TTC TAT A-3). Expression of the pMAL-C2-VP19 construct and an
empty pMAL-C2 vector (control) was performed in Escherichia coli DH5 cells.
A partial VP28 fragment (without the N-terminal hydrophobic region [1-29])
was amplified from genomic WSSV DNA by PCR with primer VP28PF (3-AAG
GAT CCC ACA ACA CTG TGA CCA AG-5) and primer VP28PR (3-TAG
CGG CCG CAA AAG CAC GAT TTA TTT AC-5) and ligated into the BamHI
and NotI sites of the pET28a vector (Novagen). Expression of the pET28a-VP28
construct and the pET28a vector (control) was performed in BL21 cells.
Protein production and inactivation. The MBP-VP19, His6-VP28, and control
proteins were overexpressed according to the manufacturer’s instructions and
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (10) and Western blot (17) with a WSSV polyclonal antiserum (21). The
bacterial concentration after inactivation was determined with a Beckman DU-
7500 photo spectrometer, where an optical density at 600 nm of 1 equaled 109
bacteria per ml. The bacteria were inactivated in 0.5% formaldehyde, incubated
for 15 min at 20°C, checked for inactivation levels, and stored at 4°C until further
use.
Coating of feed pellets. Commercial pellets weighing approximately 0.02 g
(Coppens International) were each coated with approximately 108 inactivated
bacteria or with phosphate-buffered saline for the positive and negative controls.
The inactivated bacteria were centrifuged, washed twice in phosphate-buffered
saline, and resuspended in phosphate-buffered saline. The bacteria were subse-
quently mixed with the food pellets and incubated on ice for 15 min to allow
absorption of the bacterial suspension and coated with cod liver oil to prevent
dispersion of the inactivated bacteria in the water.
Vaccination experiments. In the vaccination experiments, groups of 15 shrimp
were vaccinated by feeding coated food pellets for 7 days, as indicated in Table
1. For experiment 1, the vaccination was directly followed by a 7-h immersion
challenge in WSSV-containing seawater of a predetermined dilution as described
above. For experiment 2, the four groups were subdivided into three even
subgroups after the 7 days of vaccination, which were subsequently challenged at
3, 14, and 21 days postvaccination.
Statistical analysis. Statistical analysis of the obtained time-mortality relation-
ships was performed with Kaplan-Meier survival analysis (4) at a 5% confidence
level. The protection against WSSV after vaccination was calculated as relative
FIG. 1. Coomassie stained SDS-PAGE gel of E. coli-overexpressed
VP19 in pMAL-c2, VP28 in pET28a, empty pMAL-C2, and empty
pET28a. Lane M, size markers (kilodaltons). Lane 1, MBP-VP19 ex-
pression. Lane 2, His6-VP28 expression. Lane 3, pMAL-C2 expression.
Lane 4, pET28a expression. Numbers on the left side indicate the
positions of markers, and arrows indicate the MBP-VP19 and His6-
VP28 overexpression products.
FIG. 2. Time-mortality relationship of vaccination experiment 1.
Cumulative mortality rates of shrimp from the experimental groups
vaccinated with VP19 (), VP28 (}), VP19 plus VP28 (), pET plus
pMAL (), positive control (Œ), and negative control () as indicated
in Table 1 are plotted against the time after challenge. Lines marked
with an asterisk are significantly different from the pET plus pMAL
and positive control groups.
TABLE 1. Setup for vaccination experiments
Expt.
no Group Coating
No. of
shrimp in
group
1 VP19 pMAL-VP19 15
VP28 pET28a-VP28 15
VP19  VP28 pMAL-VP19  pET28a-VP28 15
pET  pMAL pET28a  pMAL-C2 15
Positive control PBS 15
Negative control PBS 5
2 VP28 pET28a-VP28 15  3
pET pET28a 15  3
Positive control PBS 15  3
Negative control PBS 10  3
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percent survival, calculated as (1  vaccinated group mortality/control group
mortality)  100 (3).
RESULTS
Protein production and purification. The two major WSSV
envelope proteins VP19 and VP28 were selected for use as
subunit vaccines. Multiple expressions were performed in E.
coli, with complete and partial open reading frames and MBP
and His6 tag fusions. The highest expression of VP28 was
obtained in fusion with the His6 tag when the N-terminal
hydrophobic domain was omitted. Expression for VP19 was
generally lower and highest in fusion with MBP. Bands corre-
sponding to the fusion proteins were observed at the expected
heights (Fig. 1, lanes 1 and 2). The viral origin of the band was
confirmed by Western analysis with anti-WSSV polyclonal an-
tiserum (data not shown). Empty pMAL-C2 and pET28a vec-
tors were overexpressed as control proteins according to the
same protocols (Fig. 1, lanes 3 and 4).
Vaccination experiments. (i) Experiment 1: VP19 and VP28
vaccination. In this experiment, the vaccinating potential of
WSSV envelope proteins VP19, VP28, and a mixture of both
proteins via oral administration was tested. Four groups of 15
shrimp each were vaccinated as indicated in Table 1, directly
followed by an immersion challenge. The resulting time-mor-
tality relationship of this experiment is shown in Fig. 2. The
positive control group and the group vaccinated with a mixture
of the empty pMAL-C2 and pET28a vectors showed a cumu-
lative mortality of 67% and 77%, respectively. The group vac-
cinated with VP19 also showed a high cumulative mortality of
83%, indicating that no protection could be obtained with this
protein. However, vaccination with either VP28 alone or a
mixture of VP28 and VP19 resulted in lower mortalities of
30% and 50% compared to the group vaccinated with the
empty vectors (relative survival values of 61% and 31%, re-
spectively). This mortality was significantly lower for the VP28-
vaccinated group compared to the pMAL-C2/pET28a and
positive control groups. Randomly selected survivors were
checked for the presence of WSSV, and all tested negative.
(ii) Experiment 2: onset and duration of vaccination with
VP28. As the first experiment demonstrated that vaccination
with VP28 resulted in higher survival upon WSSV challenge,
the nature of this protection was analyzed further. Shrimp were
vaccinated with WSSV envelope protein VP28, and three con-
trol groups were included, as indicated in Table 1. After vac-
cination, the four groups were subdivided into three even sub-
groups for subsequent challenge at three different time points.
The first challenge was 3 days after vaccination had stopped,
and the resulting time-mortality relationship is shown in Fig.
3a. The pET group showed a cumulative mortality of 85% and
the positive control group a mortality of 75%. A significantly
lower cumulative mortality (30%) was observed in the group
fed VP28, resulting in relative survival of 64% and 59% com-
pared to the pET and positive control groups, respectively.
These results are consistent with an independent experiment
(data not shown), where vaccination with VP28 resulted in
relative survival values of 64% and 62% compared to the pET
and positive control groups, respectively.
For the second challenge, 7 days postvaccination, the group
fed pET and the positive control group reached cumulative
mortalities of 100% and 93%, respectively (Fig. 3b). The VP28
vaccination group showed a significantly lower mortality of
23%, resulting in relative survival values of 77% and 75%
compared to the pET and positive control groups, respectively.
Twenty-one days after the vaccinations, the third challenge was
performed. This time, the pET and positive controls groups
reached cumulative mortalities of 80 and 70%, respectively
(Fig. 3c). The positive effect of feeding VP28 was reduced, and
this group reached a cumulative mortality of 50% (not signif-
icantly different), resulting in relative survival values of 29%
FIG. 3. Time-mortality relationship of vaccination experiment 2.
Shrimp were challenged 3 days (a), 7 days (b), and 21 days (c) after
cessation of feeding coated food pellets. Cumulative mortality rates of
shrimp from the experimental groups vaccinated with VP28 (}), pET
(), positive control (Œ), and negative control () as indicated in
Table 1 are plotted against the time after challenge. Lines marked with
an asterisk are significantly different from the pET and positive control
groups.
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and 38% compared to the pET and positive control groups,
respectively. The negative control groups showed no mortality.
Randomly selected survivors from all groups were tested for
WSSV, and all tested negative.
DISCUSSION
In the study presented here, we analyzed whether viral pro-
teins can be used to elicit an immune response in shrimp,
leading to protection against WSSV. To this end we used oral
vaccination, as this is the only practical way to deliver potential
vaccines to shrimp. The challenge with WSSV was performed
by immersion, as the challenge pressure can be well controlled,
contrary to challenge via infected tissue. In a natural situation,
shrimp become infected through both oral and water-borne
routes and the gills are thought to be a major point of viral
entry (5, 18). We selected VP28 and VP19 for use in the crude
subunit vaccines because they are the most exposed proteins
abundantly present in the WSSV envelope and react strongly
with polyclonal antibodies generated against complete virions
in rabbits (21). As previous studies have shown that the major
WSSV proteins are not glycosylated (24), bacteria were chosen
for protein expression and as an antigen delivery vehicle be-
cause production for commercial applications is well estab-
lished and cheap. Vaccination against bacterial diseases in
shrimp with inactivated bacteria has been performed earlier (2,
7, 19), and a vaccine is commercially available (Norvax
ShrimpVib, Intervet International BV). As it is generally be-
lieved that the inactivated bacteria induce a general immune
stimulation in shrimp, the presence of bacteria in the subunit
vaccine might by itself have a positive effect on shrimp survival
upon WSSV challenge. However, none of the vaccines lacking
VP28 provided protection against WSSV, indicating that pro-
tection was VP28 specific. Nonetheless, the presence of the
bacterial proteins may still act as an adjuvant in the vaccina-
tion.
When a mixture of VP19 and VP28 was used, a lower rela-
tive survival value was obtained compared to the group vacci-
nated with VP28 alone. As the concentration of VP28 in the
mixture was half that in the treatment with VP28 alone, this
may suggest the existence of a dose-dependent response. Fur-
ther experiments must elucidate whether the high protection
found for up to 3 weeks after vaccination with VP28 can be
extended or further improved by a longer vaccination period,
different vaccination schemes with booster feeding, or optimi-
zation of the amount of vaccine. Challenge experiments with
other shrimp-infective viruses such as yellow head virus and
Taura syndrome virus may reveal whether the observed effect
is virus specific and give us more insight into the processes
involved in the immune response.
Previous experiments have indicated that VP28 plays an
important role in the systemic infection of WSSV in shrimp, as
it is possible to neutralize WSSV with VP28 antibodies (23). As
protection against WSSV is maintained for up to 3 weeks after
vaccination, it is unlikely that the presence of residual VP28
could block WSSV infection by blocking receptors needed by
the virus to enter shrimp cells. The way in which the protection
is obtained by the shrimp immune system remains to be re-
solved. Protection could, for example, be generated by preven-
tion of entry of WSSV by secreted neutralizing substances or
by blocking virus spread after entry. At the end of the vacci-
nation experiment, survivors were checked for the presence of
WSSV by one-step PCR, and all tested negative for WSSV,
indicating that high levels of WSSV were not present in the
shrimp. More sensitive nested PCRs could be used to monitor
the entry and possible persistence of WSSV after challenge in
vaccinated shrimp.
Altogether, these results suggest that a specific memory ex-
ists in invertebrates or more specifically in crustaceans, as the
data obtained are in line with the results found for the cope-
pod, which is a minute crustacean (9). This study is the first to
show that oral vaccination of shrimp against WSSV is possible
and opens the way for the design of practical strategies to
control WSSV and other invertebrate pathogens.
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